Gilead Sciences Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

126,80 EUR -0,52 EUR -0,41 %

14:48:16

STU

147,39 USD -0,44 USD -0,30 %

vorbörslich14:28:35

BTT

Gilead Sciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.158,26 Mrd. EUR

KGV18,10Div. Rendite2,57%

WKN885823

ISINUS3755581036

SymbolGILD

Gilead Sciences Aktien News

Sortieren:Datum Meistgelesen

20.11.25PR NewswireAspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

21.10.25PR NewswireLYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

27.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

WerbungGilead Sciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

17.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

16.07.25PR NewswireGILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm

12.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

07.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

02.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

27.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

22.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

17.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

29.04.25PR NewswireCIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs")

30.01.25PR NewswireCognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications

02.10.24PR NewswireHetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

17.04.24PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA

15.04.24PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

28.12.23MyDividendsGilead Sciences zahlt vierteljährliche Dividende an die Aktionäre

20.12.23PR NewswireRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

15.11.23PR NewswireARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

08.11.23MyDividendsGilead Sciences kündigt vierteljährliche Dividende an

04.08.23MyDividendsGilead Sciences schüttet vierteljährliche Dividende aus

28.07.23PR NewswireGILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030

24.07.23PR NewswireCognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million

Gilead Sciences News

Gilead Sciences News: auf dieser Seite finden Sie alle Gilead Sciences News und Nachrichten zur Gilead Sciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Gilead Sciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Gilead Sciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.